Board of Pharmacy Dr. Jamila Jorden Confirmation Resolution of 2026
Summary
This resolution confirms the reappointment of Dr. Jamila Jorden as the pharmacist licensed in the District member of the District of Columbia Board of Pharmacy. The appointment is for a term ending March 12, 2029. The measure is a standard Council confirmation resolution, and it also directs that copies of the adopted resolution be transmitted to the nominee and the Mayor’s Office.
The bill does not create new regulatory requirements or alter the substantive duties of the Board of Pharmacy. Instead, it implements existing appointment authority under the District of Columbia Health Occupations Revision Act of 1985 and the Confirmation Act of 1978 by filling a board seat with a qualified licensed pharmacist. Its practical effect is to maintain the Board’s membership and support continued oversight of pharmacy practice, licensure, and related professional regulation in the District.
Impact
The resolution affects District law only in the sense that it completes a personnel action authorized by the Health Occupations Revision Act, which establishes the Board of Pharmacy, and the Confirmation Act, which governs Council confirmation of mayoral nominees. It confirms a specific individual to serve as the pharmacist member of the Board through March 12, 2029, thereby preserving the Board’s composition and its ability to carry out licensing, disciplinary, and professional oversight functions for pharmacists and pharmacy practice in the District.
Sentiment
The available materials suggest a generally positive and routine sentiment around the nomination. The Mayor’s office described Dr. Jorden as a current board member with extensive pharmacy, academic, and professional experience, and the legal sufficiency review found the resolution legally unobjectionable. There are no recorded committee transcripts or votes showing opposition, and the resolution appears to be a noncontroversial confirmation of an incumbent professional appointee.
Contention
No specific points of contention are reflected in the provided record. Because there are no committee transcripts or vote tallies, there is no evidence of disagreement over Dr. Jorden’s qualifications, the Board’s role, or the confirmation process. Any potential concern would likely have centered on standard appointment review issues, but none are documented here.